Thyrocare Technologies informs about outcome of board meeting

14 May 2024 Evaluate

In continuation of prior intimation dated May 07, 2024, regarding holding of a meeting of the Board of Directors of the Company, Thyrocare Technologies has informed that the Board has at its meeting held today May 14, 2024, considered and approved the audited financial results (standalone and consolidated) for the quarter and financial year ended on March 31, 2024. Pursuant to Regulation 33(3) of SEBI Listing Regulations, the standalone and consolidated audited financial results for the quarter and financial year ended on March 31, 2024, along with the Audit Reports on said financial results issued by the Statutory Auditors of the Company, are attached as Annexure - A. Further, it has declared that the Statutory Auditors of the Company have issued unmodified opinion on both the standalone and consolidated financial results for the quarter and financial year ended on March 31, 2024. The declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached as Annexure- B. The Board has recommended a final Dividend of Rs 18 per equity share of face value of Rs 10 each for the financial year 2023-24, for approval at the ensuing Annual General Meeting. The meeting commenced at 2.20 pm and concluded at 3.20 pm today. The highlights of the financial performance of the Company are enclosed.

The above information is a part of company’s filings submitted to BSE.

Thyrocare Tech. Share Price

609.35 -11.35 (-1.83%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Aster DM Healthcare 362.80
Apollo Hospital Ent. 5850.75
Max Healthcare Inst 752.20
Narayana Hrudayalay 1190.00
Global Health 1192.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.